The potential of microRNAs as biofluid markers of neurodegenerative diseases-a systematic review

Biomarkers

Volumn 19, Issue 4, 2014, Pages 259-268

  Danborg, Pia B ^a   Simonsen, Anja H ^a   Waldemar, Gunhild ^a   Heegaard, Niels H H ^b,c  

^a Rigshospitalet   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Biofluid markers; MicroRNA; Multiple sclerosis; Parkinson's disease

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; MICRORNA;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BLOOD ANALYSIS; BRAIN DEVELOPMENT; CEREBROSPINAL FLUID ANALYSIS; CREUTZFELDT JAKOB DISEASE; DEGENERATIVE DISEASE; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DISEASE MARKER; FRONTOTEMPORAL DEMENTIA; HUMAN; MILD COGNITIVE IMPAIRMENT; MULTIPLE SCLEROSIS; NERVOUS SYSTEM DEVELOPMENT; NEUROLOGIC DISEASE; PARKINSON DISEASE; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMA; REVIEW; SALIVA ANALYSIS; SERUM; SYSTEMATIC REVIEW; TAUOPATHY; URINALYSIS; BLOOD; COGNITIVE DEFECT; NEURODEGENERATIVE DISEASES;

BIOLOGICAL MARKERS; COGNITION DISORDERS; HUMANS; MICRORNAS; NEURODEGENERATIVE DISEASES;

EID: 84901310774     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2014.904001     Document Type: Review

References (87)

1. Alexandrov PN, Dua P, Hill JM, et al. (2012). microRNA (miRNA) speciation in Alzheimer's disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF). Int J Biochem Mol Biol 3:365-73
2. Angerstein C, Hecker M, Paap BK, et al. (2012). Integration of MicroRNA databases to study MicroRNAs associated wiThmultiple sclerosis. Mol Neurobiol 45:520-35
3. Arora H, Qureshi R, Jin S, et al. (2011). miR-9 and let-7g enhance the sensitivity to ionizing radiation by suppression of NFkappaB1. Exp Mol Med 43:298-304
4. Baraniskin A, Kuhnhenn J, Schlegel U, et al. (2011). Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood 117: 3140-6
5. Bekris LM, Lutz F, Montine TJ, et al. (2013). MicroRNA in Alzheimer's disease: An exploratory study in brain, cerebrospinal fluid and plasma. Biomarkers 18:455-66
6. Biomarkers Definition Working Group. (2001). Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89-95
7. Bouchard M, Suchowersky O. (2011). Tauopathies: One disease or many? Can J Neurol Sci 38:547-56
8. Carlsen AL, Schetter AJ, Nielsen CT, et al. (2013). Circulating microRNA expression profiles associated wiThsystemic lupus erythematosus. Arthritis Rheum 65:1324-34
9. Chan EK, Ceribelli A, Satoh M. (2013). MicroRNA-146a in autoimmunity and innate immune responses. Ann Rheum Dis 72: Ii90-5
10. Chen F, Hu SJ. (2012). Effect of microRNA-34a in cell cycle, differentiation, and apoptosis: A review. J Biochem Mol Toxicol 26: 79-86
11. Cheng HH, Yi HS, Kim Y, et al. (2013). Plasma processing conditions substantially influence circulating microRNA biomarker levels. PLoS One 8:e64795
12. Cogswell JP, Ward J, Taylor IA, et al. (2008). Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis 14: 27-41. (Pubitemid 352039013
13. Coolen M, Bally-Cuif L. (2009). MicroRNAs in brain development and physiology. Curr Opin Neurobiol 19:461-70
14. Cortez MA, Calin GA. (2009). MicroRNA identification in plasma and serum: A new tool to diagnose and monitor diseases. Expert Opin Biol Ther 9:703-11
15. Cox MB, Cairns MJ, Gandhi KS, et al. (2010). MicroRNAs miR-17 and miR-20a inhibit T cell activation genes and are under-expressed in MS whole blood. PLoS One 5:e12132
16. De FB, Guida M, Guida M, et al. (2012). A miRNA signature in leukocytes from sporadic amyotrophic lateral sclerosis. Gene 508: 35-40
17. De SG, Ferracin M, Biondani A, et al. (2010). Altered miRNA expression in T regulatory cells in course of multiple sclerosis. J Neuroimmunol 226:165-71
18. Dimmeler S, Nicotera P. (2013). MicroRNAs in age-related diseases. EMBO Mol Med 5:180-90
19. Du C, Liu C, Kang J, et al. (2009). MicroRNA miR-326 regulates TH-17 differentiation and is associated wiThthe pathogenesis of multiple sclerosis. Nat Immunol 10:1252-9
20. Duttagupta R, Jones KW. (2013). The curious case of miRNAs in circulation: Potential diagnostic biomarkers? Wiley Interdiscip Rev RNA 4:129-38
21. Fenoglio C, Cantoni C, De RM, et al. (2011). Expression and genetic analysis of miRNAs involved in CD4+ cell activation in patients wiThmultiple sclerosis. Neurosci Lett 504:9-12
22. Freischmidt A, Muller K, Ludolph AC, Weishaupt JH. (2013). Systemic dysregulation of TDP-43 binding microRNAs in amyotrophic lateral sclerosis. Acta Neuropathol Commun 1:42. doi:10.1186/ 2051-5960-1-42
23. Gallego JA, Gordon ML, Claycomb K, et al. (2012). In vivo microRNA detection and quantitation in cerebrospinal fluid. J Mol Neurosci 47: 243-8
24. Garcia-Gimenez JL, Sanchis-Gomar F, Lippi G, et al. (2012). Epigenetic biomarkers: A new perspective in laboratory diagnostics. Clin Chim Acta 413:1576-82
25. Gascon E, Gao FB. (2012). Cause or effect: Misregulation of microRNA pathways in neurodegeneration. Front Neurosci 6:48. doi: 10.3389/ fnins.2012.00048
26. Geekiyanage H, Jicha GA, Nelson PT, Chan C. (2012). Blood serum miRNA: Non-invasive biomarkers for Alzheimer's disease. Exp Neurol 235:491-6
27. Guerau-De-Arellano M, Smith KM, Godlewski J, et al. (2011). Micro-RNA dysregulation in multiple sclerosis favours pro-inflammatory T-cell-mediated autoimmunity. Brain 134:3578-89
28. Haghikia A, Haghikia A, Hellwig K, et al. (2012). Regulated microRNAs in the CSF of patients wiThmultiple sclerosis: A casecontrol study. Neurology 79:2166-70
29. Harraz MM, Eacker SM, Wang X, et al. (2012). MicroRNA-223 is neuroprotective by targeting glutamate receptors. Proc Natl Acad Sci USA 109:18962-7
30. Hebert SS, De SB. (2009). Alterations of the microRNA network cause neurodegenerative disease. Trends Neurosci 32:199-206
31. Heegaard NH, Schetter AJ, Welsh JA, et al. (2012). Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer 130:1378-86
32. Ji L, Chen X. (2012). Regulation of small RNA stability: Methylation and beyond. Cell Res 22:624-36
33. Jovicic A, Zaldivar Jolissaint JF, Moser R, et al. (2013). MicroRNA-22 (miR-22) overexpression is neuroprotective via general anti-Apoptotic effects and may also target specific Huntington's disease-related mechanisms. PLoS One 8:e54222
34. Junker A. (2011). Pathophysiology of translational regulation by microRNAs in multiple sclerosis. FEBS Lett 585:3738-46
35. Junker A, Hohlfeld R, Meinl E. (2011). The emerging role of microRNAs in multiple sclerosis. Nat Rev Neurol 7:56-9
36. Junker A, Krumbholz M, Eisele S, et al. (2009). MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain 132:3342-52
37. Katz R. (2004). Biomarkers and surrogate markers: An FDA perspective. NeuroRx 1:189-95
38. Keller A, Leidinger P, Lange J, et al. (2009). Multiple sclerosis: MicroRNA expression profiles accurately differentiate patients wiThrelapsing-remitting disease from healthy controls. PLoS One 4:e7440
39. Keller A, Leidinger P, Steinmeyer F, et al. (2014). Comprehensive analysis of microRNA profiles in multiple sclerosis including nextgeneration sequencing. Mult Scler 20:295-303
40. Lehmann SM, Kruger C, Park B, et al. (2012). An unconventional role for miRNA: Let-7 activates Toll-like receptor 7 and causes neurodegeneration. Nat Neurosci 15:827-35
41. LiW, Ruan K. (2009). MicroRNA detection by microarray. Anal Bioanal Chem 394:1117-24
42. Lindberg RL, Hoffmann F, Mehling M, et al. (2010). Altered expression of miR-17-5p in CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients. Eur J Immunol 40:888-98
43. Liston A, Papadopoulou AS, Danso-Abeam D, Dooley J. (2012). MicroRNA-29 in the adaptive immune system: Setting the threshold. Cell Mol Life Sci 69:3533-41
44. Lorenzi JC, Brum DG, Zanette DL, et al. (2012). miR-15a and 16-1 are downregulated in CD4+ T cells of multiple sclerosis relapsing patients. Int J Neurosci 122:466-71
45. Lukiw WJ, Alexandrov PN. (2012). Regulation of complement factor H (CFH) by multiple miRNAs in Alzheimer's disease (AD) brain. Mol Neurobiol 46:11-19
46. Lukiw WJ, Alexandrov PN, Zhao Y, et al. (2012). Spreading of Alzheimer's disease inflammatory signaling through soluble micro-RNA. Neuroreport 23:621-6
47. Machida A, Ohkubo T, Yokota T. (2013). Circulating microRNAs in the cerebrospinal fluid of patients wiThbrain diseases. Methods Mol Biol 1024:203-9
48. Margis R, Margis R, Rieder CR. (2011). Identification of blood microRNAs associated to Parkinsonis disease. J Biotechnol 152: 96-101
49. Martinelli-Boneschi F, Fenoglio C, Brambilla P, et al. (2012). MicroRNA and mRNA expression profile screening in multiple sclerosis patients to unravel novel pathogenic steps and identify potential biomarkers. Neurosci Lett 508:4-8
50. Martins M, Rosa A, Guedes LC, et al. (2011). Convergence of miRNA expression profiling, alpha-synuclein interacton and GWAS in Parkinson's disease. PLoS One 6:e25443
51. Millan MJ. (2011). MicroRNA in the regulation and expression of serotonergic transmission in the brain and other tissues. Curr Opin Pharmacol 11:11-22
52. Moya PR, Wendland JR, Salemme J, et al. (2013). miR-15a and miR-16 regulate serotonin transporter expression in human placental and rat brain raphe cells. Int J Neuropsychopharmacol 16:621-9
53. Müller M, Kuiperij HB, Claassen JA, et al. (2014). MicroRNAs in Alzheimer's disease: Differential expression in hippocampus and cellfree cerebrospinal fluid. Neurobiol Aging 35:152-8
54. Nana-Sinkam SP, Croce CM. (2013). Clinical applications for microRNAs in cancer. Clin Pharmacol Ther 93:98-104
55. Nelson PT, Keller JN. (2007). RNA in brain disease: No longer just ''the messenger in the middle''. J Neuropathol Exp Neurol 66:461-8
56. Noorbakhsh F, Ellestad KK, Maingat F, et al. (2011). Impaired neurosteroid synthesis in multiple sclerosis. Brain 134:2703-21
57. Otaegui D, Baranzini SE, Armananzas R, et al. (2009). Differential micro RNA expression in PBMC from multiple sclerosis patients. PLoS One 4:e6309
58. Pacifici M, Delbue S, Ferrante P, et al. (2013). Cerebrospinal fluid miRNA profile in HIV-encephalitis. J Cell Physiol 228:1070-5
59. Paraboschi EM, Solda G, Gemmati D, et al. (2011). Genetic association and altered gene expression of mir-155 in multiple sclerosis patients. Int J Mol Sci 12:8695-712
60. Prince M, Prina M, Guerchet M. (2013). World Alzheimer Report 2013
61. Pritchard CC, Kroh E, Wood B, et al. (2012). Blood cell origin of circulating microRNAs: A cautionary note for cancer biomarker studies. Cancer Prev Res (Phila) 5:492-7
62. Puoti G, Bizzi A, Forloni G, et al. (2012). Sporadic human prion diseases: Molecular insights and diagnosis. Lancet Neurol 11:618-28
63. Redell JB, Moore AN, Ward III NH, et al. (2010). Human traumatic brain injury alters plasma microRNA levels. J Neurotrauma 27: 2147-56
64. Ren G, Kang Y. (2013). A one-Two punch of miR-126/126 against metastasis. Nat Cell Biol 15:231-3
65. Schipper HM, Maes OC, Chertkow HM, Wang E. (2007). MicroRNA expression in Alzheimer blood mononuclear cells. Gene Regul Syst Bio 1:263-74
66. Schonrock N, Matamales M, Ittner LM, Gotz J. (2012). MicroRNA networks surrounding APP and amyloid-beta metabolism-implications for Alzheimer's disease. Exp Neurol 235:447-54
67. Serpente M, Fenoglio C, Villa C, et al. (2011). Role of OLR1 and its regulating hsa-miR369-3p in Alzheimer's disease: Genetics and expression analysis. J Alzheimers Dis 26:787-93
68. Sheinerman KS, Tsivinsky VG, Crawford F, et al. (2012). Plasma microRNA biomarkers for detection of mild cognitive impairment. Aging (Albany, NY) 4:590-605
69. Sheinerman KS, Umansky SR. (2013). Circulating cell-free microRNA as biomarkers for screening, diagnosis and monitoring of neurodegenerative diseases and other neurologic pathologies. Front Cell Neurosci 7:150. doi: 10.3389/fncel.2013.00150
70. Shi W, Du J, Qi Y, et al. (2012). Aberrant expression of serum miRNAs in schizophrenia. J Psychiatr Res 46:198-204
71. Siegel SR, Mackenzie J, Chaplin G, et al. (2012). Circulating microRNAs involved in multiple sclerosis. Mol Biol Rep 39:6219-25
72. Sievers C, Meira M, Hoffmann F, et al. (2012). Altered microRNA expression in B lymphocytes in multiple sclerosis: Towards a better understanding of treatment effects. Clin Immunol 144:70-9
73. Sondergaard HB, Hesse D, Krakauer M, et al. (2013). Differential microRNA expression in blood in multiple sclerosis. Mult Scler 19:1849-57
74. Sosa-Ortiz AL, Acosta-Castillo I, Prince MJ. (2012). Epidemiology of dementias and Alzheimer's disease. Arch Med Res 43:600-8
75. Sun AX, Crabtree GR, Yoo AS. (2013). MicroRNAs: Regulators of neuronal fate. Curr Opin Cell Biol 25:215-21
76. Tal TL, Tanguay RL. (2012). Non-coding RNAs-novel targets in neurotoxicity. Neurotoxicology 33:530-44
77. Tay Y, Kats L, Salmena L, et al. (2011). Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell 147:344-57
78. Teplyuk NM, Mollenhauer B, Gabriely G, et al. (2012). MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro Oncol 14:689-700
79. Treiber T, Treiber N, Meister G. (2012). Regulation of microRNA biogenesis and function. Thromb Haemost 107:605-10
80. Villa C, Fenoglio C, De RM, et al. (2011). Role of hnRNP-A1 and miR-590-3p in neuronal death: Genetics and expression analysis in patients wiThAlzheimer disease and frontotemporal lobar degeneration. Rejuvenation Res 14:275-81
81. Wang H, Peng W, Ouyang X, et al. (2012). Circulating microRNAs as candidate biomarkers in patients wiThsystemic lupus erythematosus. Transl Res 160:198-206
82. Wang WX, Rajeev BW, Stromberg AJ, et al. (2008). The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci 28:1213-23. (Pubitemid 351186356
83. Waschbisch A, Atiya M, Linker RA, et al. (2011). Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis. PLoS One 6:e24604
84. Weber JA, Baxter DH, Zhang S, et al. (2010). The microRNA spectrum in 12 body fluids. Clin Chem 56:1733-41
85. Weigelt K, Bergink V, Burgerhout KM, et al. (2013). Down-regulation of inflammation-protective microRNAs 146a and 212 in monocytes of patients wiThpostpartum psychosis. Brain Behav Immun 29:147-55
86. WHO fact sheets. (2013). WHO Media Centre-dementia. Fact sheet No 362. Available from: Http://www.who.int/mediacentre/factsheets/ fs362/en/ [last accessed 28 March 2014].
87. Zhang Y, Ueno Y, Liu XS, et al. (2013). The MicroRNA-17-92 cluster enhances axonal outgrowThin embryonic cortical neurons. J Neurosci 33:6885-94